BioCentury | Jun 28, 2010
Company News

Phytopharm management update

...Metabolic, Inflammation Hired: Tim Sharpington as CEO and a director, founder and former CEO of Serentis Ltd....
BioCentury | Jun 25, 2009
Strategy

Science for export

...LSE:SUMM) Drug discovery and toxicology services 2003 Abingdon, U.K. $45.1M Surface Therapeutics Ltd. (acquired by Serentis...
BioCentury | Apr 13, 2009
Clinical News

SRD441: Phase II started

...to evaluate topical SRD441 for 28 days in patients with mild to moderate atopic dermatitis. Serentis Ltd....
BioCentury | Mar 9, 2009
Company News

Serentis management update

Serentis Ltd. , Cambridge, U.K. Business: Dermatology, Other Hired: Robert Tansley as CMO, previously development and medical director of Sosei R&D Ltd. WIR Staff Dermatology...
BioCentury | Mar 9, 2009
Clinical News

SRD174: Phase IIa started

...a double-blind, placebo-controlled, crossover, U.S. Phase IIa trial to evaluate topical SRD174 in 58 patients. Serentis Ltd....
BioCentury | Jan 5, 2009
Finance

2009 Financial Markets Preview: Weathering (nuclear)winter

...provides an opportunity to pick up quality assets," Marchington said. "One of our U.K.-based investments, Serentis Ltd....
...Bethesda, Md. Orexigen Therapeutics Inc. (NASDAQ:OREX), San Diego, Calif. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Serentis Ltd....
BioCentury | Aug 18, 2008
Company News

Serentis board of directors update

Serentis Ltd. , Cambridge, U.K. Business: Dermatology, Other Appointed: Bill Blair, CEO of Adamant Biomedical Investments Ltd.’s Adamant Ventures subsidiary WIR Staff Dermatology...
BioCentury | Aug 13, 2008
Financial News

Serentis adds to series A round

...Private Equity, the Scottish Widows healthcare venture fund; and East Hill participated in the round. Serentis...
...to start Phase II testing next year. Bill Blair, CEO of Adamant Ventures, will join Serentis'...
BioCentury | Nov 5, 2007
Company News

Serentis Inc. management update

Serentis Inc. , Cambridge, U.K. Business: Dermatology, Other Hired: Peter Keen as corporate development and finance director, former CFO of Arakis Ltd. WIR Staff Dermatology...
BioCentury | Oct 8, 2007
Company News

Serentis Inc., Surface Therapeutics Ltd. deal

...Serentis acquired Surface for an undisclosed amount of stock. Serentis has four compounds in preclinical testing...
...is STP-01a/ST-441 AUREOSTAT, a protease inhibitor that is in preclinical testing to treat atopic dermatitis. Serentis...
Items per page:
1 - 10 of 13
BioCentury | Jun 28, 2010
Company News

Phytopharm management update

...Metabolic, Inflammation Hired: Tim Sharpington as CEO and a director, founder and former CEO of Serentis Ltd....
BioCentury | Jun 25, 2009
Strategy

Science for export

...LSE:SUMM) Drug discovery and toxicology services 2003 Abingdon, U.K. $45.1M Surface Therapeutics Ltd. (acquired by Serentis...
BioCentury | Apr 13, 2009
Clinical News

SRD441: Phase II started

...to evaluate topical SRD441 for 28 days in patients with mild to moderate atopic dermatitis. Serentis Ltd....
BioCentury | Mar 9, 2009
Company News

Serentis management update

Serentis Ltd. , Cambridge, U.K. Business: Dermatology, Other Hired: Robert Tansley as CMO, previously development and medical director of Sosei R&D Ltd. WIR Staff Dermatology...
BioCentury | Mar 9, 2009
Clinical News

SRD174: Phase IIa started

...a double-blind, placebo-controlled, crossover, U.S. Phase IIa trial to evaluate topical SRD174 in 58 patients. Serentis Ltd....
BioCentury | Jan 5, 2009
Finance

2009 Financial Markets Preview: Weathering (nuclear)winter

...provides an opportunity to pick up quality assets," Marchington said. "One of our U.K.-based investments, Serentis Ltd....
...Bethesda, Md. Orexigen Therapeutics Inc. (NASDAQ:OREX), San Diego, Calif. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Serentis Ltd....
BioCentury | Aug 18, 2008
Company News

Serentis board of directors update

Serentis Ltd. , Cambridge, U.K. Business: Dermatology, Other Appointed: Bill Blair, CEO of Adamant Biomedical Investments Ltd.’s Adamant Ventures subsidiary WIR Staff Dermatology...
BioCentury | Aug 13, 2008
Financial News

Serentis adds to series A round

...Private Equity, the Scottish Widows healthcare venture fund; and East Hill participated in the round. Serentis...
...to start Phase II testing next year. Bill Blair, CEO of Adamant Ventures, will join Serentis'...
BioCentury | Nov 5, 2007
Company News

Serentis Inc. management update

Serentis Inc. , Cambridge, U.K. Business: Dermatology, Other Hired: Peter Keen as corporate development and finance director, former CFO of Arakis Ltd. WIR Staff Dermatology...
BioCentury | Oct 8, 2007
Company News

Serentis Inc., Surface Therapeutics Ltd. deal

...Serentis acquired Surface for an undisclosed amount of stock. Serentis has four compounds in preclinical testing...
...is STP-01a/ST-441 AUREOSTAT, a protease inhibitor that is in preclinical testing to treat atopic dermatitis. Serentis...
Items per page:
1 - 10 of 13